<DOC>
	<DOCNO>NCT02601378</DOCNO>
	<brief_summary>This study characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) preliminary anti-tumor activity LXS196 single agent patient metastatic uveal melanoma .</brief_summary>
	<brief_title>A Phase I Study LXS196 Patients With Metastatic Uveal Melanoma .</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>Key Metastatic uveal melanoma ( histologically cytologically confirm ) judge progressive Willingness provide newly obtain tumor tissue baseline treatment unless contraindicate medical risk Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm CT scan . ECOG performance status â‰¤ 1 Key Malignant disease treat study Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . Treated brain metastasis must stable least 1 month . Impaired cardiac function clinically significant cardiac disease Patients receive treatment medication discontinue prior study entry consider following : know possible risk QT prolongation know strong inducer inhibitor CYP3A4/5 know inducer inhibitor Pgp know substrate CYP3A4/5 Pgp narrow therapeutic index Patients abnormal laboratory value define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>Metastatic uveal melanoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>LXS196</keyword>
	<keyword>PKC inhibitor</keyword>
	<keyword>dose escalation</keyword>
</DOC>